The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Abstract
Myeloid-derived suppressor cells (MDSC) are generated during tumor progression and suppress the anti-tumor functions of T and natural killer (NK) cells. Their enrichment is associated with a bad prognosis and a worse outcome of immunotherapy in cancer patients. The cytokine interleukin (IL)-6 was found to be a crucial regulator of MDSC accumulation and activation as well as a factor, stimulating tumor cell proliferation, survival, invasiveness and metastasis. Accordingly, IL-6 can serve as a negative prognostic marker in cancer. On the other hand, this cytokine is also involved in T cell activation. This review discusses the pleiotropic effects of IL-6 on immune cell populations that are critical for tumor development, such as MDSC and T cells, and summarizes the data on targeting IL-6 or IL-6 receptor (IL-6R) for tumor immunotherapy to block MDSC-mediated immunosuppression in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationInterleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Acute phase reaction and acute phase proteins
Gruys, E., Toussaint, M. J. M., Niewold, T. A., & Koopmans, S. J. (2005) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.2005.b1045 · Cited by 1,080
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Condamine, T., & Gabrilovich, D. I. (2011) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 845
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., & Umansky, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 839
Self-citationHoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 763
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730
The two faces of IL-6 in the tumor microenvironment
Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693
Hirano, T., Taga, T., Nakano, N., Yasukawa, K., Kashiwamura, S., Shimizu, K., Nakajima, K., Pyun, K. H., & Kishimoto, T. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.16.5490 · Cited by 677
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 606
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B., McQuinn, C. W., Loftus, S., Nordquist, E., Cruz-Monserrate, Z., Yu, L., Young, G., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 539
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Self-citationB cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.
Lotz, M., Jirik, F., Kabouridis, P., Tsoukas, C., Hirano, T., Kishimoto, T., & Carson, D. A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.3.1253 · Cited by 527
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 507
Pan, P.-Y., Ma, G., Weber, K. J., Ozao-Choy, J., Wang, G., Yin, B., Divino, C. M., & Chen, S.-H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1882 · Cited by 467
Chun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Heink, S., Yogev, N., Garbers, C., Herwerth, M., Aly, L., Gasperi, C., Husterer, V., Croxford, A. L., Möller-Hackbarth, K., Bartsch, H. S., et al. (2017) · Nature Immunology · doi:10.1038/ni.3632 · Cited by 386
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
Self-citationIL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
McLoughlin, R. M., Jenkins, B. J., Grail, D., Williams, A. S., Fielding, C. A., Parker, C. R., Ernst, M., Topley, N., & Jones, S. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501794102 · Cited by 333
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
Wölfle, S. J., Strebovsky, J., Bartz, H., Sähr, A., Arnold, C., Kaiser, C., Dalpke, A. H., & Heeg, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201040979 · Cited by 323
Fernando, M. R., Reyes, J. L., Iannuzzi, J., Leung, G., & McKay, D. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094188 · Cited by 314
Liu, C.-Y., Wang, Y.-M., Wang, C.-L., Feng, P.-H., Ko, H.-W., Liu, Y.-H., Wu, Y.-C., Chu, Y., Chung, F.-T., Kuo, C.-H., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0634-0 · Cited by 313
Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320011 · Cited by 299
Raber, P. L., Thevenot, P., Sierra, R., Wyczechowska, D., Halle, D., Ramirez, M. E., Ochoa, A. C., Fletcher, M., Velasco, C., Wilk, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28622 · Cited by 297
Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer
Vuk‐Pavlović, S., Bulur, P. A., Lin, Y., Qin, R., Szumlanski, C. L., Zhao, X., & Dietz, A. B. (2010) · The Prostate · doi:10.1002/pros.21078 · Cited by 266
Weide, B., Martens, A., Zelba, H., Stutz, C., Derhovanessian, E., Di Giacomo, A. M., Maio, M., Sucker, A., Schilling, B., Schadendorf, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2508 · Cited by 261
IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients
Ma, Y., Ren, Y., Dai, Z.-J., Wu, C.-J., Ji, Y.-H., & Xu, J. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/62120 · Cited by 250
Stiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0691 · Cited by 244
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 230
Fisher, D. T., Chen, Q., Skitzki, J. J., Muhitch, J. B., Zhou, L., Appenheimer, M. M., Vardam, T. D., Weis, E. L., Passanese, J., Wang, W.-C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44952 · Cited by 229
Brimnes, M. K., Vangsted, A. J., Knudsen, L. M., Gimsing, P., Gang, A. O., Johnsen, H. E., & Svane, I. M. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02463.x · Cited by 215
Angevin, E., Tabernero, J., Elez, E., Cohen, S. J., Bahleda, R., van Laethem, J.-L., Ottensmeier, C., Lopez-Martin, J. A., Clive, S., Joly, F., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2200 · Cited by 203
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Wouters, M. C. A., Kenter, G. G., van Erkel, A. R., van Poelgeest, M. I. E., Nijman, H. W., van der Hoeven, J. J. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv309 · Cited by 197
LPS and TNFα induce SOCS3 mRNA and inhibit IL‐6‐induced activation of STAT3 in macrophages
Bode, J. G., Nimmesgern, A., Schmitz, J., Schaper, F., Schmitt, M., Frisch, W., Häussinger, D., Heinrich, P. C., & Graeve, L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01662-2 · Cited by 196
Trovato, R., Fiore, A., Sartori, S., Canè, S., Giugno, R., Cascione, L., Paiella, S., Salvia, R., De Sanctis, F., Poffe, O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0734-6 · Cited by 189
Wegiel, B., Bjartell, A., Culig, Z., & Persson, J. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23261 · Cited by 179
Sharma, M. D., Hou, D.-Y., Baban, B., Koni, P. A., He, Y., Chandler, P. R., Blazar, B. R., Mellor, A. L., & Munn, D. H. (2010) · Immunity · doi:10.1016/j.immuni.2010.11.022 · Cited by 175
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells
Jourdan, M., Veyrune, J., Vos, J. D., Redal, N., Couderc, G., & Klein, B. (2003) · Oncogene · doi:10.1038/sj.onc.1206423 · Cited by 170
Jiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T. J., Utikal, J., & Umansky, V. (2015) · International Journal of Cancer · doi:10.1002/ijc.29297 · Cited by 169
Self-citationRossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Shinriki, S., Jono, H., Ota, K., Ueda, M., Kudo, M., Ota, T., Oike, Y., Endo, M., Ibusuki, M., Hiraki, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0287 · Cited by 163
Chen, M., Kuan, F., Yen, T., Lu, M., Lin, P.-Y., Chung, Y.-H., Chen, W., & Lee, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2368 · Cited by 158
Liu, H., Shen, J., & Lü, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.128 · Cited by 157
van Cruijsen, H., van der Veldt, A. A. M., Vroling, L., Oosterhoff, D., Broxterman, H. J., Scheper, R. J., Giaccone, G., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Boven, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0656 · Cited by 148
Fleming, V., Hu, X., Weller, C., Weber, R., Groth, C., Riester, Z., Hüser, L., Sun, Q., Nagibin, V. S., Kirschning, C. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0053 · Cited by 145
Self-citationYaseen, M. M., Abuharfeil, N. M., Darmani, H., & Daoud, A. K. (2020) · Open Biology · doi:10.1098/rsob.200111 · Cited by 145
Jordan, K. R., Amaria, R. N., Ramirez, O., Callihan, E., Gao, D., Borakove, M., Manthey, E., Borges, V. F., & McCarter, M. D. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1475-x · Cited by 144
Sumida, K., Wakita, D., Narita, Y., Masuko, K., Terada, S., Watanabe, K., Satoh, T., Kitamura, H., & Nishimura, T. (2012) · European Journal of Immunology · doi:10.1002/eji.201142335 · Cited by 143
Danilin, S., Merkel, A. R., Johnson, J., Johnson, R. W., Edwards, J., & Sterling, J. A. R. (2012) · OncoImmunology · doi:10.4161/onci.21990 · Cited by 143
Lin, Y., Yang, X., Liu, W., Li, B., Yin, W., Shi, Y., & He, R. (2017) · Oncogene · doi:10.1038/onc.2016.516 · Cited by 142
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Weber, R., Riester, Z., Hüser, L., Sticht, C., Siebenmorgen, A., Groth, C., Hu, X., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000949 · Cited by 139
Self-citationPossible Role for Tocilizumab, an Anti–Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
Ando, K., Takahashi, F., Motojima, S., Nakashima, K., Kaneko, N., Hoshi, K., & Takahashi, K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2020 · Cited by 135
IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer
Chen, M., Lin, P., Wu, C., Chen, W., & Wu, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061901 · Cited by 132
Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer
Feng, L., Qi, Q., Wang, P., Chen, H., Chen, Z., Meng, Z., & Liu, L. (2018) · Journal of International Medical Research · doi:10.1177/0300060518800588 · Cited by 125
Curnow, J., Scheel‐Toellner, D., Jenkinson, W. E., Raza, K., Durrani, O. M., Faint, J., Rauz, S., Wloka, K., Pilling, D., Rose‐John, S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.5290 · Cited by 119
Ku, A. W., Muhitch, J. B., Powers, C. A., Diehl, M. R., Kim, M., Fisher, D. T., Sharda, A. P., Clements, V. K., O’Loughlin, K. L., Minderman, H., et al. (2016) · eLife · doi:10.7554/elife.17375 · Cited by 119
Yang, G., Shen, W., Zhang, Y., Liu, M., Zhang, L., Liu, Q., Lu, H. H., & Bo, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16386 · Cited by 118
Wu, L., Deng, Z., Peng, Y., Han, L., Liu, J., Wang, L., Li, B., Zhao, J., Jiao, S., & Wei, H. (2017) · Oncotarget · doi:10.18632/oncotarget.20164 · Cited by 114
Kampan, N. C., Xiang, S. D., McNally, O., Stephens, A. N., Quinn, M. A., & Plebanski, M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170712160621 · Cited by 109
Lin, M., Juan, C.-Y., Chang, K., Chen, W., & Kuo, M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.12.1947 · Cited by 107
IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients
Ahmad, N., Ammar, A., Storr, S. J., Green, A. R., Rakha, E. A., Ellis, I. O., & Martin, S. G. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2106-8 · Cited by 107
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106
Jin, K., Pandey, N. B., & Popel, A. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0981-3 · Cited by 99
Hoejberg, L., Bastholt, L., & Schmidt, H. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e3283543d72 · Cited by 95
Bjoern, J., Nitschke, N. J., Iversen, T. Z., Schmidt, H., Fode, K., & Svane, I. M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1100788 · Cited by 89
Li, J., Xu, J., Yan, X., Jin, K., Li, W., & Zhang, R. (2018) · Medical Science Monitor · doi:10.12659/msm.907439 · Cited by 89
Xu, M., Zhao, Z., Song, J., Lan, X., Lu, S., Chen, M., Wang, Z., Chen, W., Fan, X., Wu, F., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.01.008 · Cited by 85
Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment
Liu, Q., Yu, S., Li, A., Xu, H., Han, X., & Wu, K. (2017) · Tumor Biology · doi:10.1177/1010428317712445 · Cited by 83
Tsai, M., Chen, W., Lu, C., & Chen, M. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.02.027 · Cited by 76
Narita, Y., Kitamura, H., Wakita, D., Sumida, K., Masuko, K., Terada, S., Nakano, K., & Nishimura, T. (2013) · Journal of Immunology · doi:10.4049/jimmunol.1103797 · Cited by 75
Chen, C., Chen, W., Lu, C.-H., Wang, W., Lin, P.-Y., Lee, K., & Chen, M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.059 · Cited by 69
Zou, M., Zhang, X., & Xu, C. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0251-7 · Cited by 65
Hope, J. C., Cumberbatch, M., Fielding, I., et al. (1995) · PubMed · Cited by 37
Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function
Nejad, E. B., Labrie, C., van der Sluis, T. C., van Duikeren, S., Franken, K. L. M. C., Roosenhoff, R., Arens, R., van Hall, T., & van der Burg, S. H. (2020) · International Journal of Cancer · doi:10.1002/ijc.33280 · Cited by 27
The role of interleukin-6 in gynaecological malignancies
Coward, J. I. G., & Kulbe, H. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.08.005 · Cited by 26
Liang, B., Li, L., Miao, R., Wang, J., Chen, Y., Li, Z., Zou, X., & Zhou, M. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1597103 · Cited by 22
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
Self-citationLin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Lai, P., Liu, L., Bancaro, N., Troiani, M., Calì, B., Li, Y., Chen, J., Singh, P. K., Arzola, R. A., Attanasio, G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.005 · Cited by 174
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
Metadata
- Authors
- Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J., & Umansky, V.
- Venue
- Cellular Immunology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 359
- Pages
- 104254
- ISSN
- 0008-8749 (ISSN-L)
- OpenAlex
- W3109289585
- Cited by
- 309
- References
- 99
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.